History of lung Cancer Managment and State of the Art

Join us Thursday, January 27th at 7pm ET as Dr. Chandra Belani will be kicking off the SAB 2022 Educational Webinar Series. Dr. Belani will present how the global trends in lung cancer incidence have started to decline and why. He will discuss how increasing utilization of lung cancer screening, understanding the biology along with the novel diagnostics strategies and precision treatments have been transformative for the lung cancer patients, investigators and researchers. Reduction in lung cancer mortality has had a major impact on overall survival from “cancer”. Precision medicine is leading to recognition of mutations/alterations in lung cancer cells and development of specific inhibitors and targeted agents.

EGFR, ALK, ROS1, MET, RET, NTRK, RAF and most recently KRAS are the NSCLC sub-types with approved treatments. The management landscape for lung cancer is truly multi-disciplinary and dynamic. Integration of chemotherapy, targeted therapy and now immunotherapy along with surgery and radiotherapy and defining mechanisms of sensitivity and resistance to current therapies have unraveled the complexities in lung cancer management. He will further explain that new vulnerabilities of lung cancer and uncharacterized biomarkers are still the focus of ongoing research.